University of Groningen
The gut microbiota in cardiovascular disease
Brandsma, Eelke Thijs
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Brandsma, E. T. (2019). The gut microbiota in cardiovascular disease: Interactions between the diet,
microbiota and the gut immune barrier. Rijksuniversiteit Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Stellingen
1. The gut microbiota is an essential factor to consider in the design of animal experiments (this
thesis)
2. Stimulating the capacity of the gut microbiota to produce SCFA is beneficial to systemic
inflammation and atherogenesis (Kasahara K, Nature Microbiology volume 3, pages 1461–
1471 (2018))
3. The intestinal immune barrier plays an important role in the progression of atherogenesis
(this thesis)
4. Dampening chronic inflammation on top of cholesterol lowering therapies is required to
further reduce cardiovascular disease risk (Ridker PM, N Engl J Med. 2017; 37:1119-113; this
thesis)
5. The gut microbiota is a future therapeutic target to lower systemic inflammation in the
pathology of cardiovascular disease (this thesis)
6. A better understanding of the interactions between bacterial species, their metabolites and
the host is essential to successfully use the gut microbiota as a therapeutic target (this thesis)
7. Although observational next-generation sequencing studies are essential for the field of
microbiota research, the scientific field should also pay attention to the development of ex-vivo culturing techniques (this thesis)
8. A reduction in α-diversity of the gut microbiota does not affect disease development (this
thesis)
9. “The more I learn, the more I realize how much I don’t know” (Albert Einstein)
10. “All disease begins in the gut” (Hippocrates)
